JCB, Volume 18, Number 4, 2012 Editorial Vol.18 No. 4 (2012) The Birth of a Discipline Arlen Meyers Bioentrepreneurship is a new academic discipline Article Vol.18 No. 4 (2012) Not fully harmonized: Differences in biotechnology patenting between Europe and the United States Brian R Dorn There has been a trend of worldwide harmonization of patent laws. Due to the continuing harmonization, examination of patents in Europe and the United States are very similar. However Article Vol.18 No. 4 (2012) CROs in Modern-day China Steven S Ma Contract research organization (CRO) outsourcing has become a critical strategy for multinational biopharmaceutical companies looking to reduce costs, time-to-market and expanding their p Article Vol.18 No. 4 (2012) Analyzing the Broadening Scope of Patentability in the Advancing Field of Biotechnology Jessica Downing The current U.S. patent system is considered to provide the broadest patent protection of all patent systems in existence, especially with respect to the biotechnology industry. Advances in Article Vol.18 No. 4 (2012) Biotechnology in Brazil: An Industry Overview Ezequiel Zylberberg Recently becoming the sixth largest economy in the world, Brazil has relied, in large part, on its comparative advantages of resource extraction and agriculture. Sustained long-term growt From the Classroom Vol.18 No. 4 (2012) The University of California, Davis, collaborative model for biotechnology education and training Judith Ann Kjelstrom UC Davis and its partners are addressing the need for innovation and entrepreneurship in graduate education and training. This paper will showcase the Designated Emphasis From the Boardroom Vol.18 No. 4 (2012) Biomarketing strategy and tactics 101 PART III of III Dimitris Dogramatzis The American Marketing Association defines marketing as the activity, set of institutions, and processes for creating, communicating, delivering, and exchanging offerings that have v Special Section Vol.18 No. 4 (2012) Lessons on Emerging Markets and Global Health Victoria Y. Fan Special Section Vol.18 No. 4 (2012) Global Health Diplomacy and Management Mechanisms of US-China Public Health Collaborations in China: Lessons for Emerging Markets Matthew David Brown Special Section Vol.18 No. 4 (2012) Emerging Markets and Differential Pricing Policies: A Question of Global Health? James Class Over the past decades, global health has moved from discrete disease campaigns to major developmental strategies. However, medication affordability remains an important, unsolved challeng Special Section Vol.18 No. 4 (2012) Tipping Point: Biosimilars, Emerging Markets, and Public-Private Engagement to Promote Global Health Bryan A Liang Biosimilars, also known as follow on biologics, are complex biotechnology drugs that are similar, but not identical, to original biologic drug forms, and represent potential lower cost ve Special Section Vol.18 No. 4 (2012) Globalization, Evolution and Emergence of Direct-to-Consumer Advertising: Are Emerging Markets the Next Pharmaceutical Marketing Frontier? Timothy Ken Mackey Pharmaceutical marketing has rapidly evolved over the past century and has now entered the digital revolution. This is exemplified by the rise of direct-to-consumer-advertising (†Special Section Vol.18 No. 4 (2012) The Partnership for Safe Medicines-India: Lessons for Emerging Markets Bejon Kumar Misra While medicines are always expected to be a safe remedy for human ailments, unfortunately, there is also the phenomenon of ‘unsafe medicines’ due to unscrupulous elements in Special Section Vol.18 No. 4 (2012) Blood Supply and Safety in the Developing World: Considerations for Emerging Markets William Riley Assuring a safe and adequate blood supply in developing nations such as emerging markets is a daunting challenge that directly affects fundamental health metrics of a country. Numerous mo
